Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceria-ALI
- Development stage
- Preclinical
- Lead developer
- Ceria Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
Ceria-ALI is a nanoparticle-based RNA therapeutic developed by Ceria Therapeutics for the treatment of acute lung injury (ALI). The drug utilizes a cerium oxide nanoparticle (CNP) platform to deliver a microRNA-146a (miR-146a) mimic. Its mechanism of action involves the suppression of Interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6), which are key signaling molecules in the Toll-like receptor 4 (TLR4)/NF-κB-mediated inflammatory pathway. By inhibiting this pathway, Ceria-ALI aims to reduce the hyper-inflammatory response associated with ALI and prevent progression to acute respiratory distress syndrome (ARDS). The program is currently in the IND-enabling stage.
- Other names
- CNP-miR146aCNP-miR-146aCNP-miR 146aCeria CNP-miR146a
02
Targets
IRAK1 (Interleukin-1 receptor-associated kinase 1)TRAF6
Beyond the preview
Go deeper on Ceria-ALI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ceria-ALI.